Eli Lilly's stock rose over 5% as discussions with the Trump administration to reduce drug prices gained momentum, coinciding with significant gains in shares for Pfizer and Merck by 6% and more. These developments follow an agreement where Pfizer will cut prices by up to 85%, aiming to enhance patient access through the new 'TrumpRx' initiative. The rally in pharmaceutical stocks reflects a growing focus on affordability in healthcare as policy changes loom.
“Eli Lilly · closed · up · more than +5%”
“Eli Lilly and other major drugmakers · are in · active discussions · with the Trump administration”
“S&P 500 Index · closed · up · +0.41%”
“Dow Jones Industrials Index · closed · up · +0.18%”
“Nasdaq 100 Index · closed · up · +0.28%”
“December E-mini S&P futures · rose · up · +0.39%”
“December E-mini Nasdaq futures · rose · up · +0.26%”
“Pfizer · agreed to · slash some drug prices · by up to 85%”
“Eli Lilly · is in discussions with · the Trump administration · to expand patient access”
“US government · will shut down · if lawmakers fail to pass a spending bill · by this evening”
“US government · would pause · most federal operations · if lawmakers failed to reach an agreement”
“US Sep MNI Chicago PMI · unexpectedly fell · to 40.6 · -0.9”
.svg&width=160)
